CRVS
- Corvus Pharmaceuticals, Inc.
()
Overview
Company Summary
Corvus Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel products to treat cancer and other related diseases. The company's main focus is on developing innovative immunotherapies that enhance the body's immune response to fight against cancer.
Corvus Pharmaceuticals primarily focuses on developing drugs that target and inhibit certain immune checkpoints, which are proteins that can prevent the immune system from recognizing and attacking cancer cells effectively. By targeting these immune checkpoints, Corvus aims to activate and empower the immune system to better combat cancer.
One of the key products under development by Corvus Pharmaceuticals is CPI-006, a monoclonal antibody that targets the CD73 enzyme. CD73 plays a role in preventing an effective immune response against cancer. By inhibiting CD73, CPI-006 has the potential to enhance anti-tumor immunity and improve patient outcomes.
The company also has several other immuno-oncology programs in its pipeline, including targeted antibodies and small molecules designed to modulate the immune system's response to cancer. Additionally, Corvus Pharmaceuticals collaborates with other pharmaceutical companies and research institutions to advance its research and accelerate the development of potential treatments.
In summary, Corvus Pharmaceuticals focuses on developing immunotherapies that activate the immune system to fight cancer by inhibiting immune checkpoints. Through its innovative approaches and pipeline of potential treatments, the company aims to make meaningful advancements in the field of oncology and improve patient outcomes.